TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25651491
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (lipid emulsion eye drops, omega-3 supplements, eyelid cleansing wipes)
Study: 9834008
Drug: Current use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current use of any oral contraceptive (OC)
Study: 9834008
Drug: Noncurrent use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncurrent use of oral contraceptives (OC)
Study: 9834008
Drug: Different generations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different generations of oral contraceptives
Study: 9691922
Drug: Leu13‐motilin (KW‐5139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leu13‐motilin (KW‐5139) infusion at doses of 2, 4, 8, and 16 pmol/kg/min
Study: 9691922
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% NaCl) infusion
Study: 1681680
Drug: Zuclopenthixol decanoate
Normalized name: zuclopenthixol decanoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zuclopenthixol decanoate (ZPT‐D) 100‐600 mg every 4 weeks
Study: 1681680
Drug: Haloperidol decanoate
Normalized name: Haloperidol Decanoate
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol decanoate (HAL‐D) 38‐200 mg every 4 weeks
Study: 28385397
Drug: L-proline supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-proline supplementation during early pregnancy
Study: 28385397
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no L-proline supplementation)
Study: 18054445
Drug: Hospital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital treatment as usual without additional counselling (Control)
Study: 12759298
Drug: Fenofibrate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (300 mg once daily) plus anti-hyperuricaemic agents (including benzbromarone 50 mg once daily or allopurinol 200 mg twice a day)
Study: 12759298
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg once daily) plus anti-hyperuricaemic agents (including benzbromarone 50 mg once daily or allopurinol 200 mg twice a day)
Study: 8815570
Drug: Fragmin (2500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fragmin (2500 IU sc once daily for 90 days)
Study: 1945215
Drug: Hydration group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration group (2 L of water plus usual fluid)
Study: 27128831
Drug: Bazedoxifene 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene 80 mg
Study: 27128831
Drug: Bazedoxifene (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene (5 mg and greater)
Study: 27128831
Drug: Bazedoxifene (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene (various doses)
Study: 27128831
Drug: Bazedoxifene (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene (1, 2.5, 5, 10, 20, 40, and 80 mg)
Study: 17686444
Drug: 3- and
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3- and 4-drug regimens
Study: 3576660
Drug: Carbamazepine tablets
Normalized name: Carbamazepine Tablets
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine tablets
Study: 1222752
Drug: Carbamazepine syrup
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine syrup
Study: 1222752
Drug: Carbamazepine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (both preparations)
Study: 31175806
Drug: Flaxseed lignan
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed lignan supplement (50 mg secoisolariciresinol diglucoside/d)
Study: 31175806
Drug: Flaxseed lignan
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed lignan supplement
Study: 25381193
Drug: Baseline first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline first phase insulin response (FPIR) ≤3 μU/mL during IvGTT
Study: 25381193
Drug: Maximal plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal plasma glucose ≥11.1 mmol/L measured at 30, 60 and/or 90 min during OGTT
Study: 25381193
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FPIR from IvGTT and maximal plasma glucose during OGTT
Study: 23162100
Drug: K‐citrate (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: K‐citrate (60 mEq daily)
Study: 16882343
Drug: Home UVB
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home UVB treatment
Study: 8237086
Drug: Sitting position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitting position with liquid bolus (5 ml water)
Study: 8237086
Drug: Supine position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supine position with liquid bolus (5 ml water)
Study: 27393622
Drug: nab-paclitaxel with
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel with concurrent bevacizumab followed by AC
Study: 23424755
Drug: Lymphdiaral Basistropfen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphdiaral Basistropfen (verum) - 10 drops three times daily for 105 days
Study: 23424755
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 10 drops three times daily for 105 days
Study: 16110851
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (Propranolol + ISMN)
Study: 12448042
Drug: Evidence-Based Medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-Based Medicine (EBM)
Study: 8520875
Drug: IL-2 treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IL-2 treatment alone (41 patients)
Study: 8520875
Drug: IL-2 treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IL-2 treatment with interferon gamma (33 patients)
Study: 2405326
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (lidocaine/prilocaine) applied 1-75 minutes before CO2 laser treatment
Study: 2405326
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied 1-75 minutes before CO2 laser treatment
Study: 649204
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg thrice daily for seven days
Study: 649204
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 2400 mg
Study: 649204
Drug: Two 2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 2400 mg doses on successive days
Study: 649204
Drug: 2400 mg
Normalized name: pancreatin 2400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2400 mg dosages
Study: 17130680
Drug: Omalizumab (150,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (150, 225, 300, or 375mg) administered subcutaneously every 2 or 4 weeks
Study: 12584276
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 150 mg/day for 4 weeks
Study: 10675831
Drug: Conjugated estrogen-medrogestone
Normalized name: estrogens, conjugated (USP) / medrogestone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen-medrogestone combination
Study: 9116774
Drug: r-FSH with
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-FSH with LHRH agonist
Study: 9116774
Drug: r-FSH without
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-FSH without LHRH agonist
Study: 1439226
Drug: Breath-actuated metered
Normalized name: QVAR Redihaler 80 MCG/ACTUAT Breath-Actuated Metered Dose Inhaler, 120 ACTUAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breath-actuated metered dose inhaler (Aerolin in the Autohaler inhalation device)
Study: 1439226
Drug: Standard press
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard press and breathe metered dose inhaler
Study: 19118696
Drug: Ranibizumab (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.3 mg or 0.5 mg)
Study: 21626816
Drug: Cerebrolysin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (50 ml)
Study: 9027792
Drug: Cefuroxime 1.5
Normalized name: cefuroxime 1.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 1.5 g i.v. preoperatively and 250 mg i.p. in the first dialysis bag (1 litre fluid)
Study: 8104044
Drug: Serazepine (CGS‐15040A)
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serazepine (CGS‐15040A) at doses greater than or equal to 10 mg
Study: 3089950
Drug: Ordinary lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary lithium carbonate (1.5 g)
Study: 3089950
Drug: Sustained-release lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release lithium carbonate (1.8 g)
Study: 27461133
Drug: Lactobacillus reuteri-containing
Normalized name: Lactobacillus reuteri-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri-containing lozenges (≥108 CFU L. reuteri ATCC PTA 5289 and ≥108 CFU L. reuteri DSM 17938, consumed 2× daily for approx. 7 weeks)
Study: 31157556
Drug: Lactobacillus reuteri-containing
Normalized name: Lactobacillus reuteri-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri-containing lozenges
Study: 27461133
Drug: Placebo (devoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (devoid of L. reuteri)
Study: 21677121
Drug: Free lutein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free lutein (fL) 12.2 mg
Study: 21677121
Drug: Lutein esters
Normalized name: lutein esters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein esters (Le) 27 mg (equivalent to 13.5 mg free lutein)
Study: 17307425
Drug: Unopposed estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unopposed estrogen (conjugated estrogen, 0.625 mg)
Study: 17307425
Drug: Estrogen +
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen + medroxyprogesterone acetate (MPA, 2.5 mg)
Study: 17307425
Drug: Women who
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women who took >80% of study medication
Study: 12943952
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily (flx20)
Study: 12943952
Drug: Fluoxetine 40
Normalized name: fluoxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 40 mg daily (flx40)
Study: 12943952
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg plus buspirone 20 mg daily (flx20-plus-buspirone)
Study: 10682871
Drug: Standard Purine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Purine soy formula (180 mg purines/L from RNA)
Study: 10682871
Drug: Reduced Purine
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced Purine soy formula (65 mg purines/L; 26 mg/L from RNA and 39 mg/L from ribonucleotides)
Study: 9054254
Drug: Propofol plus
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol plus high-dose esmolol (bolus of 1 mg/kg, then 250 micrograms.kg-1.min-1)
Study: 9054254
Drug: Propofol plus
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol plus low-dose esmolol (bolus of 0.5 mg/kg, then 50 micrograms.kg-1.min-1)
Study: 8356866
Drug: High-flow anaesthesia
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow anaesthesia using a partial rebreathing system without carbon dioxide absorption (Mapleson D)
Study: 8356866
Drug: Medium-flow anaesthesia
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-flow anaesthesia using a circle system with carbon dioxide absorption
Study: 8356866
Drug: Low-flow anaesthesia
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow anaesthesia using a circle system with carbon dioxide absorption
Study: 2868255
Drug: Dietary manipulation
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary manipulation therapy
Study: 31797330
Drug: Cognitive remediation-enabled
Normalized name: Enablex
DrugBank: Darifenacin (DB00496)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cognitive remediation-enabled cognitive behaviour therapy (CR-CBT)
Study: 24748630
Drug: Golimumab (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab (50 mg or 100 mg) from week 24 onward
Study: 23764521
Drug: Aripiprazole 2
Normalized name: aripiprazole 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 2 mg/day (Phase 1) and 5 mg/day (Phase 2)
Study: 23764521
Drug: Aripiprazole 2
Normalized name: aripiprazole 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 2 mg/day (Phase 2)
Study: 27111239
Drug: Alendronate (ALN)
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate (ALN) 10 mg/day
Study: 19580465
Drug: Alendronate (ALN)
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate (ALN) 5 mg/day
Study: 18664276
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi (10 modified forms from classical Yang style Tai Chi), 60-minute sessions, twice weekly for 12 weeks
Study: 18664276
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control (wellness education and stretching), 60-minute sessions, twice weekly for 12 weeks
Study: 12607326
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg bid, Amoxicillin 750 mg bid, Clarithromycin 200 mg bid
Study: 12607326
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg bid, Amoxicillin 750 mg bid, Clarithromycin 400 mg bid
Study: 12607326
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg, Amoxicillin 750 mg bid, Clarithromycin 400 mg bid
Study: 12607326
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg, Amoxicillin 1,000 mg, Clarithromycin 500 mg bid
Study: 11391837
Drug: zalcitabine 2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: zalcitabine 2.25 mg and saquinavir 1800 mg per day
Study: 6509283
Drug: Phenobarbitone 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone 30 mg
Study: 6509283
Drug: Phenobarbitone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone 100 mg
Study: 28722569
Drug: Annual mass
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual mass azithromycin distributions (3 treatments during high-transmission season)
Study: 28722569
Drug: Biannual mass
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biannual mass azithromycin distributions (6 treatments: 3 during high-transmission season and 3 during low-transmission season)
Study: 16964669
Drug: Interferon-alpha-2b treatment
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha-2b treatment during vaccination (Group A, 12 patients)
Study: 16964669
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine without interferon (Group B, 25 patients)
Study: 9287255
Drug: Psychological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatment conditions for IBS
Study: 8330445
Drug: L‐thyroxine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐thyroxine therapy
Study: 3090332
Drug: Bolus MMC
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus MMC with no further treatment (Group A)
Study: 3090332
Drug: Oral futraful
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral futraful for one year without MMC induction (Group C)
Study: 3090332
Drug: Bolus MMC
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus MMC injection and oral futraful (Group B)
Study: 3090332
Drug: Bolus MMC
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus MMC and oral futraful for one year (Group B)
Study: 30625042
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) patch treatments
Study: 30625042
Drug: Platelet-derived patch
Normalized name: Platelet-derived growth factor BB, recombinant
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Platelet-derived patch treatment and PRP injection
Study: 19501932
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with vitamin K2 (VK; menatetrenone; 45 mg/day) and angiotensin-converting enzyme inhibitor (ACE-I; perindopril; 4 mg/day) for 36-48 months
Study: 19501932
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (VK; menatetrenone; 45 mg/day)
Study: 19501932
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor (ACE-I; perindopril; 4 mg/day)
Study: 2475682
Drug: Sustained-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release verapamil (240 mg once daily)
Study: 28301686
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment with daily site-specific oral hygiene using fluoridated toothpaste, professional topical fluoride treatment, and dietary advice.
Study: 23444228
Drug: Ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3 mg/kg plus gp100 vaccine
Study: 23444228
Drug: Ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3 mg/kg plus placebo
Study: 23400564
Drug: gp100 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp100 vaccine plus placebo
Study: 19725594
Drug: CNTO 528
Normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTO 528 at 0.03 mg/kg
Study: 19725594
Drug: CNTO 528
Normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTO 528 at 0.09 mg/kg
Study: 19725594
Drug: CNTO 528
Normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTO 528 at 0.3 mg/kg
Study: 19725594
Drug: CNTO 528
Normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTO 528 at 0.9 mg/kg
Study: 17724294
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/day (n = 43)
Study: 17724294
Drug: Statin withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin withdrawal compared to non-randomized patients without previous statin therapy (n = 126)
Study: 15134708
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline injection into the right trapezius muscle
Study: 15134708
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline injection into the right trapezius muscle
Study: 15134708
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline injection into the right temporalis muscle
Study: 15134708
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline injection into the right temporalis muscle
Study: 9728842
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of intrathecal ropivacaine plus sufentanil 10 microg (R2)
Study: 9728842
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of intrathecal ropivacaine plus sufentanil 10 microg (R4)
Study: 9728842
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of intrathecal bupivacaine plus sufentanil 10 microg (B)
Study: 29368880
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy group (N=20)
Study: 23837278
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% (10 mL)
Study: 23334115
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75% (10 mL)
Study: 18471341
Drug: lornoxicam (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: lornoxicam (16 mg, i.v.)
Study: 16311286
Drug: Ephedrine 50
Normalized name: Ephedrine 50 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 50 mg in saline 0.9% w/v, 500 ml at 999 ml h(‐1)
Study: 16311286
Drug: Phenylephrine 500
Normalized name: acetaminophen-phenylephrine 500 mg-5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 500 microg in saline 0.9% w/v, 500 ml at 999 ml h(‐1)
Study: 8856257
Drug: Dialysis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis with dialysate containing 128 mEq/l sodium
Study: 8856257
Drug: Dialysis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis with dialysate containing 137 mEq/l sodium
Study: 8737627
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg brotizolam